| 1.16 0 (0%) | 09-13 15:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.74 | 1-year : | 2.09 |
| Resists | First : | 1.49 | Second : | 1.78 |
| Pivot price | 1.14  |
|||
| Supports | First : | 1 | Second : | 0.84 |
| MAs | MA(5) : | 1.16 |
MA(20) : | 1.23 |
| MA(100) : | 1.8 |
MA(250) : | 10.06 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 32 |
D(3) : | 30.8 |
| RSI | RSI(14): 37.3 | |||
| 52-week | High : | 42.5 | Low : | 1 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CLDI ] has closed below upper band by 32.4%. Bollinger Bands are 92.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 90 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.21 - 1.22 | 1.22 - 1.22 |
| Low: | 1.15 - 1.15 | 1.15 - 1.16 |
| Close: | 1.15 - 1.16 | 1.16 - 1.17 |
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors. The company was founded in 2014 and is based in San Diego, California.
Mon, 09 Sep 2024
Calidi Biotherapeutics stock target cut by Baird with Outperform tag maintained - Investing.com
Thu, 22 Aug 2024
Calidi Biotherapeutics Unveils Redtail Biopharma Subsidiary - TipRanks
Tue, 13 Aug 2024
Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results - StockTitan
Mon, 29 Jul 2024
Calidi Biotherapeutics Secures Investment, Expands Advisory Board - TipRanks
Mon, 29 Jul 2024
Calidi Biotherapeutics Announces Launch of Nova Cell Subsidiary and $3 Million Aggregate Investment from Dr. Ronald Rigor - StockTitan
Thu, 18 Jul 2024
Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 35 (M) |
| Shares Float | 21 (M) |
| Held by Insiders | 47.4 (%) |
| Held by Institutions | 5 (%) |
| Shares Short | 11 (K) |
| Shares Short P.Month | 14 (K) |
| EPS | -0.59 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.03 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -173 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.78 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -26 (M) |
| Levered Free Cash Flow | -39 (M) |
| PE Ratio | -1.97 |
| PEG Ratio | 0 |
| Price to Book value | -38.67 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.61 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|